Year-end Sale % OFF 
Abstract
Meeting abstracts Systemic lupus erythematosus is a chronic, heterogeneous autoimmune disease, and there is no specific drug for its effective treatment, which may be because of its complexity on pathogenic mechanism. A multitude of studies of SLE in the last decade have accentuated a central role
Highlights
Systemic lupus erythematosus is a chronic, heterogeneous autoimmune disease, and there is no specific drug for its effective treatment, which may be because of its complexity on pathogenic mechanism
The Clinical Trials have proved the effectiveness of antibodies targeting multiple human IFN-a subtypes, especially the sifalimumab of AstraZeneca (IIb)
A novel fully human antibody that neutralizes multiple human IFN-a subtypes effectively was screened from fully synthetic human antibody library by Institute of Biotechnology, Academy of Military Medical Sciences
Summary
Systemic lupus erythematosus is a chronic, heterogeneous autoimmune disease, and there is no specific drug for its effective treatment, which may be because of its complexity on pathogenic mechanism. A novel fully human monoclonal antibody that neutralizes multiple human IFN-a subtypes effectively: a candidate therapy for SLE
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
